WallStSmart

GE Vernova LLC (GEV)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 15% more annual revenue ($45.20B vs $39.38B). GEV leads profitability with a 23.8% profit margin vs 15.1%. TMO appears more attractively valued with a PEG of 1.56. GEV earns a higher WallStSmart Score of 67/100 (B-).

GEV

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 4.3Quality: 4.3
Piotroski: 4/9Altman Z: 1.02

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 5.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GEV.

TMOSignificantly Overvalued (-16.1%)

Margin of Safety

-16.1%

Fair Value

$408.60

Current Price

$465.00

$56.40 premium

UndervaluedFair: $408.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEV6 strengths · Avg: 9.2/10
Market CapQuality
$300.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
75.7%10/10

Every $100 of equity generates 76 in profit

EPS GrowthGrowth
1816.0%10/10

Earnings expanding 1816.0% YoY

Profit MarginProfitability
23.8%9/10

Keeps 24 of every $100 in revenue as profit

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Free Cash FlowQuality
$4.79B8/10

Generating 4.8B in free cash flow

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$176.32B9/10

Large-cap with strong market position

Areas to Watch

GEV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.864/10

Expensive relative to growth rate

P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

Altman Z-ScoreHealth
1.022/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

P/E RatioValuation
26.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with margins at 23.8% and operating margin at 5.5%. Revenue growth of 16.3% demonstrates continued momentum.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : GEV

The primary concerns for GEV are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

GEV profiles as a growth stock while TMO is a mature play — different risk/reward profiles.

GEV carries more volatility with a beta of 1.31 — expect wider price swings.

GEV is growing revenue faster at 16.3% — sustainability is the question.

GEV generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

GEV scores higher overall (67/100 vs 62/100), backed by strong 23.8% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?